Overview

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Lacosamide